)
Jeena Sikho Lifecare (JSLL) investor relations material
Jeena Sikho Lifecare Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Unaudited standalone and consolidated results for the quarter ended 30 June 2026 were approved by the Board after Audit Committee review.
Revenue and PAT rose YoY on standalone and consolidated bases; Q1FY27 revenue from operations was ₹22,440.48 lakh standalone and consolidated.
Growth reflected patient-volume gains, an expanding care network and 47% YoY growth in Ayurveda products; the footprint included 62 hospitals, 57 clinics and day-care centres, and 2,400 operational beds.
Financial highlights
Standalone revenue from operations was ₹22,440.48 lakh vs ₹17,428.59 lakh YoY; PAT was ₹6,569.18 lakh vs ₹5,131.14 lakh.
Consolidated revenue from operations was ₹22,440.48 lakh vs ₹17,428.59 lakh YoY; PAT was ₹6,589.01 lakh vs ₹5,127.14 lakh.
Consolidated profit before tax was ₹8,752.99 lakh vs ₹6,850.98 lakh; total income was ₹23,873.13 lakh vs ₹17,535.44 lakh.
Revenue rose 4% QoQ and 29% YoY; EBITDA was ₹9,211 lakh, up 18% QoQ and 17% YoY, while EBIT was ₹7,679 lakh, up 25% QoQ and 11% YoY.
PAT rose 45% QoQ and 28% YoY; other income was ₹1,402 lakh versus ₹358 lakh QoQ and ₹107 lakh YoY, while finance cost rose 109% YoY to ₹347 lakh.
Outlook and guidance
Around 2,400 operational beds and 450 beds in the pipeline support planned capacity-led and volume-led growth over the medium term.
A first wellness resort was signed in Manali, with plans for 108 rooms, 22 villas, a helipad and access to 20+ acres of private forest.
Planned product categories include plant-based protein, gynaecology and joint-care products; new pharmacy-channel launches are in progress.
Derabassi hospital property sale for ₹9.05 crore is expected to close by 30 September 2026; operations are planned to continue at the same premises under a proposed lease.
Derabassi contributes ~6%–8% of revenue; the sale is not expected to materially affect operations or revenue generation.
- H1 revenue, profit and operating cash flow all advanced year over year.JSLL
Q2 23/24 - FY23 revenue reached ₹204 crore as a 119-site network supported expansion.JSLL
Investor presentation - Asset-light Ayurveda services and product sales supported expansion and higher reported revenue.JSLL
Investor presentation - Q2 revenue grew 66% as margins, patient volumes and hospital capacity advanced.JSLL
Q2 25/26 - FY24 revenue grew 59% as profits doubled and operational capacity expanded.JSLL
Q4 23/24 - H1FY25 revenue and PAT rose as expansion costs weighed on EBITDA margin.JSLL
Q2 24/25 - FY25 revenue rose 45%, with 87% IPD growth as capacity expanded to 1,600 beds.JSLL
Q4 24/25 - Standalone Q3 revenue rose 92%, with PAT up 405% and 475+ beds in development.JSLL
Q3 25/26 - Revenue reached ₹17,428.59 lakh, with standalone PAT of ₹5,131.14 lakh.JSLL
Q1 25/26 - Consolidated FY26 net profit reached ₹22,169.81 lakh; proposed dividend is ₹4.50 per share.JSLL
Q4 25/26
Next Jeena Sikho Lifecare earnings date
Next Jeena Sikho Lifecare earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage
)